Home | | | Search | | | Browse | | | Resources | | | Help | | | What's New | | | About |
---|
FACTS I: A Study to Test the Safety and Effectiveness of a New Medication on the Treatment of Active Ulcerative Colitis
This study is currently recruiting patients.
Sponsored by: | Otsuka Maryland Research Institute |
---|---|
Information provided by: | Otsuka Maryland Research Institute |
Purpose
The purpose of this study is to evaluate the safety and efficacy of the drug OPC-6535 compared to a placebo in patients with active Ulcerative Colitis.
Depending on their response, participants will be offered the investigational medication for up to one year after the study’s completion at select sites.
Condition | Treatment or Intervention | Phase |
---|---|---|
Ulcerative Colitis |
Drug: OPC-6535 Tablets (drug) |
Phase III |
MedlinePlus related topics: Ulcerative Colitis
Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study
Official Title: FACTS I: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-arm Study of the Efficacy and Safety of OPC-6535 Tablets in the Treatment of Subjects with Active Ulcerative Colitis
Expected Total Enrollment: 375
Study start: May 2003
Eligibility
Ages Eligible for Study: 18 Years - 80 Years, Genders Eligible for Study: Both
Criteria
Inclusion Criteria:
Exclusion Criteria:
Additional exclusion criteria apply.
Please see study Web site for additional information.
Location and Contact Information
More Information
U.S. National Library of Medicine, Contact NLM Customer Service | ||||||||||||||
National Institutes of Health, Department of Health & Human Services | ||||||||||||||
Copyright, Privacy, Accessibility, Freedom of Information Act |